NCT03388632 2025-12-18
Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
Clinical Trials
6 trialsNCT04319198 2025-09-30
Rollover Study in Participants With Metastatic Solid Tumors Benefiting From Therapy With Sacituzumab Govitecan-hziy
Gilead Sciences
Phase 4 Completed
NCT00878423 2024-08-02
Study to Assess the Safety of Escalating Doses of AT13387 in Patients With Metastatic Solid Tumors
Astex Pharmaceuticals, Inc.
Phase 1 Completed
NCT03523390 2024-02-23
Phase I/Ib Multiple Ascending Dose Study in China
Merck KGaA, Darmstadt, Germany
Phase 1 Completed
NCT04457778 2023-12-08
First in Human Study of M6223
EMD Serono
Phase 1 Completed
NCT02235688 2022-02-10
Study to Investigate the Safety and Activity of Aldoxorubicin Plus Gemcitabine in Subjects With Metastatic Solid Tumors
ImmunityBio, Inc.
Phase 1 Completed